A Relapse Prevention Study Evaluating the Efficacy of Vortioxetine in Adults with Major Depressive Disorder

A Relapse Prevention Study Evaluating the Efficacy of Vortioxetine in Adults with Major Depressive Disorder

Brief description of study

This study will evaluate the effectiveness of Vortioxetine (aka Brintellix) in the prevention of depression relapse.

Detailed description of study

This study is being conducted to evaluate the long-term maintenance effects of individuals treated with vortioxetine (aka, Brintellix) in the prevention of depression relapse. Participants will be enrolled into a 8-16 weeks open-label treatment period. During the open-label period, all subjects will receive 10 mg Vortioxetine. At the end of the open label patients have option to go into 16 -52 week, double blind study to assess the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults with MDD.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Depression,Major depression,Depression
  • Age: Between 18 Years - 75 Years
  • Gender: All


Updated on 20 Nov 2019. Study ID: 822288

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center